Distribution and Marketing of Drugs (Second Edition) – Vietnam Chapter

November 16, 2015

Distribution and Marketing of Drugs (Second Edition) – Vietnam Chapter

Practical Law Company

The 2015 edition of Distribution and Marketing of Drugs, a guide to the distribution and marketing of drugs in 28 jurisdictions around the world, has been published. Each chapter provides an overview of the legal framework governing distribution and marketing of pharmaceuticals, including pre-conditions for distribution; licensing; wholesale distribution; marketing to consumers; marketing to professionals; and engagement with patient organizations.

The Vietnam chapter, written by Tu Ngoc Trinh and Huong Lan Nguyen, members of the Tilleke & Gibbins corporate and commercial team in Vietnam, covers the following subjects in detail:

Distribution: Pre-conditions for distribution, the process of authorization by the Drug Administration of Vietnam, special cases for importing drugs without registration, the procedural structure and costs regarding licensing a drug for distribution, and the procedure to appeal a licensing decision.
Distribution to Consumers: The categories of drugs for distribution, the persons and establishments that are authorized to distribute to consumers, the responsibilities of the Ministry of Health in Vietnam, appealing distribution decisions, and consequences of non-compliance with consumer distribution laws.
Wholesale Distribution: The legal regime regarding the wholesale of drugs, the authorities responsible for supervising wholesale distribution activities, and the legal consequences of noncompliance.
Marketing and Promotion: The general regime and limits of marketing activities, including a list of the main laws and regulations governing marketing activities of drugs in Vietnam.
Marketing to Consumers: The legal regime with respect to marketing to consumers, the types of drugs that can be advertised to consumers, the mediums of marketing that can be used, and the marketing techniques that are not permitted in Vietnam.
Marketing to Professionals: Marketing activities permitted when marketing to professionals, the extent to which Vietnam law controls meetings with groups of professionals, information that is legally required when advertising to professionals, rules on comparisons with other products, and the permissibility of discounts, free samples, and sponsoring of professionals.

Distribution and Marketing of Drugs is published by Practical Law Company, which is owned by Thomson Reuters. For more information on the publication, please visit the PLC website.

Download Full Article

Related Professionals

Tu Ngoc Trinh

Vietnam

+84 24 3772 5556

Email

Huong Lan Nguyen

Regulatory Affairs Consultant

Vietnam

+84 28 628 45678

Email

RELATED INSIGHTS

February 14, 2024

New Rules on Drug Importation for Clinical Trials Set to Take Effect in Thailand

Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA

December 15, 2023

Lex Mundi Guide to Doing Business in Thailand 2023

As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2023. This guide outlines the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Country Guides series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource for planning international business strategy and researching new markets. The full Guide to Doing Business in Thailand is available through the button below.

December 6, 2023

Laos Implements Medical Device Registration and Notification Requirements

New regulatory requirements for medical device registration and notification in Laos are set to enter into force in the coming weeks under the plan found in Notification No. 9606 to implement Decision No. 1470/MOH on Registration and Notification of Medical Devices (Decision 1470). The notification, issued on October 25, 2023, by the Food and Drug Department (FDD) under the Ministry of Health (MOH), outlines the FDD’s strategic plan for phased-in registration and notification requirements for medical devices. In the first phase, starting January 1, 2024, the FDD will initiate the registration process for class C (moderate-high risk) and D (high risk) medical devices. Meanwhile, operators dealing with class A (low risk) and B (low-moderate risk) devices can continue applying for import permits without having to register the devices or notify the FDD. In the subsequent phase, starting January 1, 2025, operators will have to notify the FDD about class A devices and complete the registration process for class B devices. To prepare for these requirements, import-export companies in the pharmaceutical and medical products sector must submit a list of medical devices, including their classification based on the country of manufacture, to the FDD by December 15, 2023. This measure is aimed at enabling the FDD to streamline the collection, guidance, and preparation processes to ensure efficient registration within the set time frame. While import-export companies can still submit their lists after either December 15, 2023, or January 1, 2024 (the registration commencement date), registration may be delayed since the FDD will prioritize those who submit their lists by the December 15 deadline. The list of medical devices should encompass medical devices imported in the past as well as those intended for future import permission applications. During the initial registration stage (i.e., from January 1, 2024), import-export companies that are

October 25, 2023

Healthcare in Cambodia: Crackdown on Illegal Advertising and Noncompliant Services

Cambodia’s Ministry of Health (MOH) continues to increase awareness among the public and private sector of the need for strict healthcare regulations and strict enforcement to advance the quality of the country’s healthcare sector. In April 2023, the MOH issued a notification letter reminding advertisers of health products that they need to obtain a permit before advertising their products in Cambodia. On October 12, 2023, the MOH issued two press releases on continued noncompliance in the healthcare sector. The two press releases address the illegal advertising of both healthcare products and private healthcare services. The releases also address unlicensed healthcare professionals and general noncompliance by private healthcare services. These releases indicate that the MOH, in cooperation with local authorities, will substantially increase its enforcement efforts across Cambodia. Since October 12, several private healthcare clinics have had their operations closed and licenses suspended or revoked, signaling the ministry’s intent to enforce the legal framework. Noncompliant Advertising of Health Products The first press release focuses on the continued illegal advertising of health products and the advertising of unregistered health products. Health products include modern medicines, traditional medicines, health supplements, medical devices, cosmetics, and other products that prevent or treat diseases. The release highlights that the MOH has noticed ongoing unauthorized and illegal advertising, commenting that these are often found online and on social media. The noncompliant advertising referenced in the release includes advertising of health products without the required advertising permit, advertising products that are not properly registered with the MOH, and advertising by unlicensed companies and individuals. The MOH also states in the release that some advertisements are using inappropriate and noncompliant content that is not based on medical science and exaggerates the qualities of the health products—specifically mentioning skin-whitening cosmetics. The ministry’s press release also informs the public of

You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

Industries

Practices

November 16, 2015